galsulfase

CHEBI:CHEBI_750925

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

generic_name
galsulfase
rxcui
584222
product_type
DRUG FOR FURTHER PROCESSING
listing_expiration_date
20251231
dosage_form
SOLUTION
active_ingredient_strength
5 mg/5mL
route
INTRAVENOUS
marketing_category
DRUG FOR FURTHER PROCESSING
labeler_name
BioMarin Pharmaceutical Inc.
manufacturer_name
BioMarin Pharmaceutical Inc.
pharm_class
Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]
pharm_class_cs
alpha-Glucosidases [CS]
nui
N0000175823
brand_name
NAGLAZYME
brand_name_base
NAGLAZYME
product_ndc
68135-020
application_number
BLA125117
marketing_start_date
20050609
package_marketing_start_date
09-JUN-05
spl_id
f6dec083-8be2-4dbc-95d4-c5a8600e7628
active_ingredient_name
GALSULFASE
package_ndc
68135-020-99
package_description
20000 mL in 1 BAG (68135-020-99)
unii
59UA429E5G
spl_set_id
59341250-deac-ed71-3823-a4f5d64dbd77
pharm_class_epc
Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class